LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the appointment of Marc Becker as Chief Financial Officer, effective January 4, 2018 . Mr. Becker is a seasoned financial executive with more than 15 years of experience in the biotechnology industry.
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc . (NASDAQ: CNCE) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on Monday, December 18, 2017 .
Conference Call Scheduled Today at 8:30 a.m. EST LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2017. "This is an exciting time for our deuterium-based chemistry as we continue to demonstrate our
CTP-543 is Being Evaluated in Moderate-to-Severe Alopecia Areata Phase 2a Trial On Track to Complete in Second Half of 2018 LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed enrollment of the first cohort of its Phase 2a trial
LEXINGTON, Mass.--( BUSINESS WIRE )-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2017 financial results on Thursday, November 9, 2017, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m.
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trials and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has denied Incyte's petition to institute inter partes review (IPR) of U.S. Patent No.
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc . (NASDAQ: CNCE) today announced that it will present a corporate overview at the Wells Fargo 2017 Healthcare Conference on Thursday, September 7, 2017 , at 11:10 a.m. EDT at the Westin Waterfront in Boston .
Conference Call Scheduled Today at 8:30 a.m. EDT LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2017. "We are very pleased that we have closed the CTP-656 asset purchase agreement with Vertex, which
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2017 financial results on Tuesday, August 8, 2017 , before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m.
BOSTON & LEXINGTON, Mass.--( BUSINESS WIRE )-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the completion of their previously announced asset purchase agreement. Under the completed agreement, Vertex now has worldwide
